- Home
- LMND vs RYTM Comparison
LMND vs RYTM Comparison
Compare LMND & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LMND | RYTM |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LMND | RYTM |
|---|---|---|
| Price | $51.77 | $89.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $60.67 | ★ $129.43 |
| AVG Volume (30 Days) | ★ 2.8M | 712.7K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $60.05 | $58.38 |
| Revenue Next Year | $31.24 | $83.95 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.31 | $45.91 |
| 52 Week High | $99.90 | $122.20 |
Technical Indicators
Market Signals| Indicator | LMND | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 33.82 | 35.17 |
| Support Level | $48.32 | $83.98 |
| Resistance Level | $60.28 | $96.92 |
| Average True Range (ATR) | 5.16 | 5.65 |
| MACD | -0.86 | -0.86 |
| Stochastic Oscillator | 12.46 | 15.42 |
Price Performance
Historical ComparisonAbout LMND Lemonade Inc.
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.